Form 4: David J. Mack Reports Stock Transaction in BioXcel Therapeutics
SEC Form 4 Filing
Director David J. Mack reports the vesting of restricted stock units in BioXcel Therapeutics, resulting in the acquisition of 27,089 shares of common stock.
Summary
- On January 31, 2025, David J. Mack, a director of BioXcel Therapeutics, Inc., reported a transaction involving restricted stock units (RSUs).
- Mack acquired 27,089 shares of common stock through the vesting of RSUs.
- Following the transaction, Mack directly owns 81,267 shares of BioXcel Therapeutics common stock.
- The RSUs were granted on November 21, 2024, and vest in twelve equal monthly installments, contingent upon continued service as a director.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing regarding stock transactions, and does not inherently convey positive or negative sentiment.
Positives
- The vesting of RSUs indicates continued alignment of the director's interests with those of the company and its shareholders.
Industry Context
This Form 4 filing is a routine disclosure related to insider transactions and provides transparency to the market regarding the holdings of company directors.
Key Dates
| Date | Description |
|---|---|
| November 21, 2024 | Date the Reporting Person was granted 325,077 RSUs |
| November 30, 2024 | Start date of the twelve equal installments of vesting RSUs |
| January 31, 2025 | Date of the reported transaction where 27,089 RSUs vested |
| February 04, 2025 | Date of the Form 4 filing |
Keywords
BioXcel Therapeutics, BTAI, Form 4, David J. Mack, Restricted Stock Units, Director, Stock Transaction, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.